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RESUMO – A doença de Paget extramamária (DPEM) é uma neoplasia maligna cutânea, rara, observada principalmente em 
mulheres caucasianas pós-menopausa. A cirurgia é o tratamento mais comum. No entanto, no que diz respeito à DPEM vulvar, 
o seu tratamento cirúrgico passa frequentemente por cirurgia radical, que pode ser mutilante e levar à perda de feminilidade. 
Recentes avanços terapêuticos têm incluído abordagem médica e multimodal médico-cirúrgico, permitindo uma maior preserva-
ção da anatomia genital e subsequente diminuição da morbilidade. Neste sentido, imiquimod tem sido utilizado, off-label, como 
monoterapia ou terapêutica adjuvante na DPEM. 
Relatamos o caso de uma mulher com DPEM extenso na área anogenital submetida a resseção cirúrgica complementada com 
reconstrução plástica e precedida de tratamento médico com imiquimod. O imiquimod neoadjuvante permitiu uma citorredução 
significativa da área tumoral, minimizando a radicalidade cirúrgica, mantendo a função local e a morfologia.
PALAVRAS-CHAVE – Doença de Paget Extramamária/tratamento; Imiquimod; Neoplasias da Vulva/tratamento; Terapia Neoad-
juvante.
Neoadjuvant use of Imiquimod Before Surgery in 
Extramammary Paget’s Disease 
ABSTRACT – Extramammary Paget's disease (EMPD) is a distinct form of a rare malignant skin neoplasm, primarily seen in post-
menopausal Caucasian women. Surgery is the most common treatment. However, concerning vulvar EMPD, radical surgery can be 
mutilating and leads to loss of femininity. Recent therapeutic development has included medical and medical-surgical approaches, 
allowing better preservation of genital anatomy with subsequent reduced morbidity. Accordingly, off-label use of imiquimod has 
been reported as a monotherapy or adjuvant therapy in EMPD. 
We report the case of a woman with extensive EMPD in the anogenital area, submitted to surgical resection complemented with 
plastic reconstruction and preceded by imiquimod medical treatment. Neoadjuvant imiquimod induced a significant cytoreduction 
of the tumor area, minimizing surgical radicality and maintaining local function and morphology
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INTRODUCTION
Extramammary Paget's disease (EMPD) is a distinct form of 
a rare malignant skin neoplasm, an intraepithelial neoplasia 
of glandular cells,1 first reported by Crocker2 in 1889 in the 
scrotum and penis. Vulvar Paget's disease was first reported in 
1901 by Dubreuilh.3 EMPD is primarily seen in postmenopausal 
Caucasian women and the most common site of involvement is 
the vulva, where it represents less than 1% of the vulvar malig-
nancies and is rarely invasive (<10%).4 It typically appears as 
erythematous, scaly or moist, eczematous lesions with irregular 
borders, accompanied by pruritus.1 Vulvar Paget's disease often 
spreads in an occult fashion extending beyond the clinically 
apparent edges of the lesion.4 These patients are at risk for a 
second synchronous or metachronous neoplasm, namely, co-
lorectal adenocarcinoma, adenocarcinoma of the cervix, carci-
noma of the transitional epithelium from the renal pelvis to the 
urethra, breast and vulvar carcinoma.5,6 Staging should inclu-
de examination of the entire cutaneous integument, evaluation 
of draining lymph nodes and exclusion of genitourinary and 
colorectal malignant tumors.5,7 Recent therapeutic modalities 
have emerged. Surgery, by default, is the most common treat-
ment, but it is challenging to excise the disease adequately, and 
recurrence is common, leading to repeated surgical procedu-
res and mutilation.4 The use of neoadjuvant therapies prior 
to surgery has been performed in many neoplasias, allowing 
tumor cytoreduction, making subsequent surgical excision ea-
sier.8 We report a case of a woman with extensive EMPD in the 
anogenital area treated with neoadjuvant imiquimod before 
excisional and reconstructive surgery.
CASE REPORT
A 67-year-old woman was referred for evaluation of a 
pruritic, anogenital lesion, resistant to topical antifungals and 
corticosteroids with months of evolution. Her medical history 
included an infiltrating ductal carcinoma of the breast 17 years 
before, submitted to left mastectomy, radiotherapy and hormo-
ne therapy. Physical examination revealed a 16 x 7 cm large, 
erythematous, scaly plaque with irregular but well demarca-
ted borders, centered by small erosions, localized in the ge-
nital and perianal areas (Fig. 1). No inguinal adenopathies 
or extragenital cutaneous lesions were found. Histopathology 
showed cells with large abundant pale-staining cytoplasm and 
large nuclei, with prominent nucleoli infiltrating the epidermis 
without dermal invasion (Fig. 2a-b). It was immunopositive for 
CK7, CEA, GCDFP-15, CAM5.2 and EMA, and negative for 
S-100 and CK20. Thorough gynecological evaluation, thora-
co-abdomino-pelvic computed tomography, pelvic magnetic 
resonance, proctoscopy and cystoscopy excluded synchronous 
malignancies. Laboratory evaluations were unremarkable 
except for syphilis serology, which reveled late latent syphilis 
promptly treated with benzathine penicillin G 2,4 million units 
weekly, 3 doses. 
The diagnosis of primary intraepithelial EMPD was confir-
med. To achieve tumor reduction before surgery patient was 
treated with imiquimod 5% cream, 3 times per week, for 12 
weeks with partial response. To maximize the clinical respon-
se, it was increased to daily application, but was stopped 5 
weeks later due to systemic symptoms (anorexia, headache 
Figure 1
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and dizziness). At this point substantial tumor reduction was 
seen (Fig. 3) and patient underwent partial bilateral vulvec-
tomy with V-Y fasciocutaneous flap reconstruction (Fig. 4). 
Histopathology revealed Paget's disease involvement of the 
surgical margins at the right labia majora of the vulva. A re-
lapse was seen after one year of follow-up (Fig. 5). The patient 
restarted imiquimod application 3 times per week, while awai-
ting surgical reintervention.
DISCUSSION
EMPD lesions are generally confined to the epidermis, but it 
can invade the dermis and metastasize to regional lymph nodes 
or distant organs.9 Mohs micrographic surgery or wide local 
excision are the traditional therapeutic options.10,11 Recently, a 
safe resection margin of 2 cm has been recommended.10,11 
EMPD lesions commonly develop in apocrine-rich areas 
such as the vulva, penis, scrotum, perianal, and axilla, conse-
quently, tissue loss and functional impairment after surgery are 
associated with significant morbidities.10,12 Concerning vulvar 
EMPD, is very important to avoid the long-term complications 
of radical surgery, such as pain and scarring, a feeling of mu-
tilation, loss of femininity and also, adverse impact on sexual 
function.4 Actually, surgeons face a huge challenge: balance 
between potentially extensive radical surgery (which allows free 
surgical margins reducing theoretically the relapse) versus con-
servative surgery (which preserves genital anatomy and func-
tion).10 Furthermore, indistinct borders, subclinical extensions 
and multifocal nature associated with EMPD result in high re-
currence rates despite adequate surgical resection margins.10,13 
In 2013, Edey et al4 published a Cochrane review evaluating 
the different treatment modalities for vulvar Paget's disease. 
They found that most studies stated that margin status had no 
impact on recurrence. Similarly, a recent review of 89 cases 
of vulvar Paget’s disease by Onaiwu et al5 found no associa-
tion between margin status and recurrence rates. Given the 
potential negative sequelae and the high rate of recurrence, a 
more conservative approach may be of benefit when there is 
no evidence of an underlying adenocarcinoma.14 
Generally, EMPD appears as carcinoma in situ and has a 
favorable prognosis. However, in about 20% of cases EMPD 
progresses to an invasive tumor, invasive EMPD (iEMPD), which 
can metastasize mainly through the lymphatic channels and 
become fatal.15 A TNM evaluation has been recently proposed 
by Ohara et al.15 
Other treatment options include topical imiquimod, to-
pical 5-fluorouracil, topical bleomycin sulfate, intralesional 
interferon-α, radiation therapy, cryotherapy, chemotherapy, 
laser ablation and photodynamic therapy.8,10 Imiquimod is a 
biological response modifier, which stimulates both innate and 
acquired immune function resulting in potent antiviral, antitu-
mor and immunoregulatory properties.1,12  After Zampogna et 
al  publication of 2 cases of primary limited cutaneous perineal 
and genital EMPD treated with imiquimod 5%,16 off-label use 
has been successfully reported as a monotherapy or adjuvant 
therapy in EMPD.1,8,9,10,12,14 A recent systematic review reported 
a response rate to imiquimod ranging from 50% to 80% with 
a recurrence rate about 20%.1 Imiquimod seems to be efficient 
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also in cases of EMPD recurrence and was reported as an in-
teresting neodjuvant treatment before surgery by Toledo et al,8 
to reduce tumor size before surgery. However, there are also 
reports of failure after imiquimod treatment in EMPD.17 The 
optimal frequency and length of treatment time remains to be 
defined.1 The intensity of imiquimod’s effect is dose-dependent 
and so the probability of local and systemic side effects is in-
creased with daily application, as experienced by our patient.12
Our patient presented with an extensive EMPD affecting 
a great part of the anogenital region. The neoadjuvant treat-
ment with imiquimod 5% cream, induced a significant chemi-
cal cytoreduction of the tumoral area (histologically confirmed 
after the excision once the periphery of the lesion was free of 
neoplasia except at one location) allowing a later surgical ex-
cision of an otherwise inoperable/highly mutilating neoplasm. 
In addition to the clinical reduction of the tumor area after 
treatment with imiquimod, histopathology revealed a comple-
te response in the margins except for one area.
CONCLUSION
Immune modulators, such as imiquimod, can be a good 
alternative as a neoadjuvant treatment previous to surgery in 
selected cases of extensive EMPD. Promising results have been 
published recently in the literature validating the need for well-
-designed clinical trials.
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